לומיקראס 120 מ"ג - Lumykras 120mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XX Other antineoplastic agents |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | LUMYKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an approved test, who have received at least one prior systemic therapy. |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××קר×ס ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | AMGEN EUROPE B.V., NETHERLANDS |
| ×©× ××¢× ×ר×ש×× | AMGEN EUROPE B.V. |
| ר×ש××× | ת×ר×× ××ש×: 6/2021. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 26/11/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־26 בנובמבר 2025 ב־17:59